Abstract

Inflammatory bowel disease 30. Hanauer SB, Sninsky CA, Robinson M, et al. An oral preparation of mesalamine as 36. Loftus EV Jr, Kane SV, Bjorkman D. Systematic review: short-term adverse effects long-term maintenance therapy for ulcerative colitis: a randomised, placebo- of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment controlled trial. Ann Intern Med 1996;124:204–11. Pharmacol Ther 2004;19:179–89. 31. Ireland A, Mason CH, Jewell DP. Controlled trial comparing olsalazine 37. Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of and sulphasalazine for the maintenance treatment of ulcerative colitis. Gut remission in ulcerative colitis. Cochrane Database Syst Rev 2006;CD000544. 1988;29:835–7. 38. Yamamoto T, Umegae S, Kitagawa T, et al. Systemic and local cytokine production 32. Kiilerich S, Ladefoged K, Rannem T, et al. Prophylactic effects of olsalazine v in quiescent ulcerative colitis and its relationship to future relapse: a prospective pilot sulphasalazine during 12 months maintenance treatment of ulcerative colitis. The study. Inflamm Bowel Dis 2005;11:589–96. Danish Olsalazine Study Group. Gut 1992;33:252–5. 39. Paoluzi OA, Iacopini F, Pica R, et al. Comparison of two different daily dosages (2.4 33. Kruis W, Judmaier G, Kayasseh L, et al. Double-blind dose-finding study of olsalazine vs. 1.2 g) of oral